Nisa Investment Advisors
TSHA icon

Nisa Investment Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Nisa Investment Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4K Buy
5,780
+673
+13% +$3.98K ﹤0.01% 1949
2026
Q1 		$22.8K Sell
5,107
-405
-7% -$1.88K ﹤0.01% 1959
2025
Q4 		$30.3K Sell
5,512
-360
-6% -$1.75K ﹤0.01% 1787
2025
Q3 		$19.2K Buy
5,872
+2,125
+57% +$6.02K ﹤0.01% 2023
2025
Q2 		$8.66K Sell
3,747
-483
-11% -$1.05K ﹤0.01% 2325
2025
Q1 		$5.88K Buy
4,230
+3,423
+424% +$5.73K ﹤0.01% 2214
2024
Q4 		$1.4K Buy
807
+303
+60% +$629 ﹤0.01% 2590
2024
Q3 		$1.01K Buy
+504
New +$1.11K ﹤0.01% 2574
2022
Q2 		– Sell
-19,800
Closed -$129K – 2511
2022
Q1 		$129K Buy
+19,800
New +$148K ﹤0.01% 1537

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nisa Investment Advisors's TSHA Position: Q2 2026 in Review

Nisa Investment Advisors increased its Taysha Gene Therapies (TSHA) stake by 13% in Q2 2026, buying an estimated $3.98K and bringing the position to 5,780 shares worth $39.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1949.

Nisa Investment Advisors first reported a position in TSHA in Q1 2022 and has held it in 9 quarters since. The position peaked at $129K in Q1 2022. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Nisa Investment Advisors held 5,780 shares of Taysha Gene Therapies worth $39.4K as of Q2 2026.
  • Nisa Investment Advisors bought 673 Taysha Gene Therapies shares in Q2 2026, an estimated $3.98K.
  • Taysha Gene Therapies made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1949 holding.
  • Nisa Investment Advisors first reported a position in Taysha Gene Therapies in Q1 2022 and has held it in 9 quarters since.
  • Nisa Investment Advisors's Taysha Gene Therapies position peaked at $129K in Q1 2022.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.